Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 7
Submit an article Journal homepage
203
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Treatment of acute bacterial exacerbations of chronic bronchitis

Ilias I Siempos Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece +30 210 683 9604; +30 210 683 9605; [email protected]
, MD,
Argyris Michalopoulos Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece +30 210 683 9604; +30 210 683 9605; [email protected]; Henry Dunant Hospital, Critical Care Department, Athens, Greece
, MD FCCP &
Matthew E Falagas Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece +30 210 683 9604; +30 210 683 9605; [email protected]; Henry Dunant Hospital, Department of Medicine, Athens, Greece; Tufts University School of Medicine, Department of Medicine, Boston, Massachusetts, USA
, MD MSc DSc
Pages 1173-1182 | Published online: 30 Apr 2009

Bibliography

  • Rabe KF, Hurd S, Anzueto A, et al. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
  • Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704
  • Llor C, Molina J, Naberan K, et al.; EVOCA study group. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract 2008;62:585-92
  • Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease: the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-67
  • Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31
  • Simoens S, Decramer M. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007;8:633-48
  • Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-64
  • MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:530-5
  • Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
  • Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21
  • Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007;8:30
  • Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;2:CD004403
  • Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60
  • Roede BM, Bresser P, Bindels PJ, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008;63:968-73
  • Roede BM, Bresser P, Prins JM, et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009;33:282-8
  • Puhan MA, Vollenweider D, Steurer J, et al. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. BMC Med 2008;6:28
  • Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-45
  • Allegra L, Blasi F, Diano P, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:742-7
  • Soler N, Agustí C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007;62:29-35
  • Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007;35:143-9
  • Burley CJ, Masterton RG, Lovell DP. Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect 2007;55:226-32
  • Nseir S, Cavestri B, Di Pompeo C, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008;76:253-60
  • Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin guidance with standard therapy. Chest 2007;131:9-19
  • Balter MS, La Forge J, Low DE, et al.; Canadian Thoracic Society; Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003;10:3B-32B
  • Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008;68:1841-54
  • Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME. Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Rev Anti Infect Ther 2008;6:861-6
  • Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008;62:442-50
  • Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93
  • Korbila IP, Manta KG, Siempos II, et al. Penicillins vs trimethoprim based regimens for acute bacterial exacerbations of chronic bronchitis: a meta-analysis of randomized controlled trials. Can Fam Physician 2009;55:60-7
  • Woodhead M, Blasi F, Ewig S, et al. European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
  • Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:S177-85
  • Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;43:107-13
  • Nseir S, Ader F. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria. Curr Opin Pulm Med 2008;14:95-100
  • Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007;132:447-55
  • Moss M, Wilkes D, Ware LB. Clinical year in review II: pulmonary infections in the immunocompetent host, issues in the training of fellows and residents, asthma, and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:745-50
  • Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007;29:1127-37
  • Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of patients with community acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008;179:1269-77
  • Wilson R, Jones P, Schaberg T, et al.; MOSAIC Study Group. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006;61:337-42
  • Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother 2008;9:1755-72
  • European Medicines Agency: Press office. European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines. Doc. Ref. EMEA/CHMP/382927/2008
  • Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004;5:1117-52
  • Wilson R, Schentag JJ, Ball P, Mandell L; 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-52
  • Cazzola M, Salvatori E, Dionisio P, Allegra L. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther 2006;19(Suppl 1):30-7
  • Concia E, Allegranzi B, Ciottoli GB, et al. Penetration of orally administered prulifloxacin into human lung tissue. Clin Pharmacokinet 2005;44:1287-94
  • Grassi C, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin Study Group. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 2002;69:217-22
  • Takagi H, Tanaka K, Tsuda H, Kobayashi H. Clinical studies of garenoxacin. Int J Antimicrob Agents 2008;32:468-74
  • Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766-77
  • Andrews J, Honeybourne D, Jevons G, et al. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 2003;51:727-30
  • Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2008;1:CD001954
  • Blasi F, Aliberti S, Tarsia P. Clinical applications of azithromycin microspheres in respiratory tract infections. Int J Nanomedicine 2007;2:551-9
  • Martinez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int J Antimicrob Agents 2005;26(Suppl 3):156-63
  • Guay DR, Gustavson LE, Devcich KJ, et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001;23:566-77
  • Halpern MT, Cifaldi MA, Schmier JK. Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections. COPD 2005;2:217-23
  • Bishai WR. Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin. Expert Rev Anti Infect Ther 2006;4:405-16
  • Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47
  • Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-90
  • Anzueto A, Bishai WR, Pottumarthy S. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. Diagn Microbiol Infect Dis 2007;57(Suppl 3):31-8
  • Sader HS, Jones RN. Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Rev Anti Infect Ther 2007;5:29-43
  • Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008;9:561-75
  • Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007;29:548-60
  • Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007;8:237-56
  • Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother 2008;42:80-90
  • McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus β2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;4:CD003900
  • Kirsten DK, Wegner RE, Jörres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993;104:1101-07
  • Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomized trials. BMJ 2003;327:643
  • Stoller JK. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;341:988-94
  • Lindenauer PK, Pekow P, Gao S, et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144:894-903
  • Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008;133:756-66
  • Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;1:CD001288
  • National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59:1-232
  • Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002;165:698-703
  • McCrory DC, Brown C, Gelfand SE, Back PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001;119:1190-209
  • Zuin R, Palamidese A, Negrin R, et al. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005;25:401-8
  • Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008;62:661-8
  • Ram FSF, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004;3:CD004104

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.